miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

Instacart outlines $9.45B–$9.6B Q4 GTV target while expanding enterprise and AI initiatives

View original at seekingalpha.com
Instacart outlines $9.45B–$9.6B Q4 GTV target while expanding enterprise and AI initiatives Earnings Call Insights: Maplebear Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NYC represents a small percentage of GTV and Instacart expects to navigate regulatory changes successfully

    80% confidence
  • Q4 adjusted EBITDA guidance is $285 million to $295 million

    80% confidence
  • 75% of the market is still in large baskets, $75 and above

    80% confidence
  • GAAP net income was $144 million, up 22% year-over-year, and adjusted EBITDA also grew 22% year-over-year to $278 million

    80% confidence
  • Q4 GTV is anticipated to range between $9.45 billion to $9.6 billion, representing 9% to 11% year-over-year growth

    80% confidence
  • Advertising and other revenue will return to double-digit growth in 2026

    80% confidence
  • Price parity retailers are growing 10 percentage points faster versus marked-up retailers

    80% confidence
  • Stock-based compensation in Q3 was $82 million, down $24 million quarter-over-quarter, and expected to normalize to Q2 2025 levels in Q4

    80% confidence
  • Exclusivity with retailers is less important than the depth of enterprise relationships

    80% confidence
  • Instacart continues to grow in markets where Amazon competes and is not seeing a shift in basket composition

    80% confidence
  • Q3 orders reached 83.4 million, up 14% year-over-year, driving GTV of $9.17 billion, up 10% year-over-year

    80% confidence
  • Large basket growth (75% of the market) remains consistent

    80% confidence
  • International expansion is the right moment, taking existing technology and extending it to retailers beyond North America

    80% confidence
  • Instacart is confident in reaching 4%-5% long-term ad take rates through platform and ecosystem expansion

    80% confidence
  • Instacart's storefront or white label e-commerce technologies now power more than 350 retailer e-commerce storefronts

    80% confidence
  • Instacart+ is a critical part of overall strategy with continued growth and engagement

    80% confidence
  • Instacart is the leading online grocery marketplace with a best-in-class suite of enterprise technologies for retailers and a growing advertising ecosystem

    80% confidence
  • Three strategic investment areas are affordability, accelerating enterprise, and ads and data

    80% confidence
  • Instacart drove over $1 billion of ads and other revenue over the past 12 months

    80% confidence
  • Over 80% of Instacart's business is nonexclusive today, and the majority of those have an enterprise relationship

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Instacart outlines $9.45B–$9.6B Q4 GTV target while expanding enterprise and AI initiatives — Source | Via News | es.VIA.NEWS